Related Experiment Video
Updated: Jul 20, 2025
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma
Chuanxu Liu1,2, Xinyu Ding3, Gaoyang Li3
1Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Abstract:
Extranodal natural killer/T cell lymphoma, nasal type (ENKTL) is an aggressive lymphoid malignancy with a poor prognosis and lacks standard treatment. Targeted therapies are urgently needed. Here we systematically investigated the druggable mechanisms through chemogenomic screening and identified that Bcl-xL-specific BH3 mimetics effectively induced ENKTL cell apoptosis. Notably, the specific accumulation of Bcl-xL, but not other Bcl-2 family members, was verified in ENKTL cell lines and patient tissues. Furthermore, Bcl-xL high expression was shown to be closely associated with worse patient survival. The critical role of Bcl-xL in ENKTL cell survival was demonstrated utilizing selective inhibitors, genetic silencing, and a specific degrader. Additionally, the IL2-JAK1/3-STAT5 signaling was implicated in Bcl-xL dysregulation. In vivo, Bcl-xL inhibition reduced tumor burden, increased apoptosis, and prolonged survival in ENKTL cell line xenograft and patient-derived xenograft models. Our study indicates Bcl-xL as a promising therapeutic target for ENKTL, warranting monitoring in ongoing clinical trials by targeting Bcl-xL.
Insights
Bcl-xL-specific BH3 mimetics show promise for treating extranodal natural killer/T cell lymphoma (ENKTL). Targeting Bcl-xL effectively induced cancer cell death and improved survival in preclinical models, suggesting a new therapeutic strategy for this aggressive lymphoma.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Extranodal natural killer/T cell lymphoma, nasal type (ENKTL) is an aggressive malignancy with limited treatment options and poor prognosis.
- Targeted therapies are critically needed to improve outcomes for ENKTL patients.
Purpose of the Study:
- To identify druggable targets and therapeutic strategies for ENKTL.
- To investigate the role of Bcl-2 family proteins, specifically Bcl-xL, in ENKTL pathogenesis and survival.
Main Methods:
- Chemogenomic screening to identify effective drug targets.
- Validation of Bcl-xL expression in ENKTL cell lines and patient tissues.
- Utilizing selective Bcl-xL inhibitors, genetic silencing, and degraders to assess its role in cell survival.
- Investigating the IL2-JAK1/3-STAT5 signaling pathway in Bcl-xL dysregulation.
- Preclinical evaluation in ENKTL xenograft models (cell line and patient-derived).
Main Results:
- Bcl-xL-specific BH3 mimetics induced significant apoptosis in ENKTL cells.
- High Bcl-xL expression was observed in ENKTL and correlated with poorer patient survival.
- Bcl-xL inhibition demonstrated a critical role in ENKTL cell death.
- The IL2-JAK1/3-STAT5 pathway was implicated in Bcl-xL dysregulation.
- In vivo studies showed reduced tumor burden, increased apoptosis, and prolonged survival with Bcl-xL inhibition.
Conclusions:
- Bcl-xL is a promising therapeutic target for extranodal natural killer/T cell lymphoma.
- Targeting Bcl-xL with BH3 mimetics offers a potential new treatment strategy for ENKTL.
- Further clinical investigation of Bcl-xL inhibitors in ENKTL is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...